Replies to post #5200 on Arbutus Biopharma Corporation (ABUS)

[DewDiligence]

ABUS/AB-506 CC—Almost all of the Q&A dealt with the fact that four HBV patients (two in each dose cohort) experienced a Grade-4 ALT flare, which caused automatic discontinuation of treatment, according to the trial protocol. These flares occurred after 14 days of monotherapy treatment.

Due to these Grade-4 ALT flares seen in HBV patients, ABUS will conduct a new 28d trial in healthy volunteers to see if there are any Grade-4 ALT flares and, if so, when they occur.